Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q3 2022 call → NOWe need to determine if management conveys that the business is currently outgrowing the company's size, with disproportionate scale relative to smallness. Look for statements about current activity, demand, commitments that are large relative to company size. Examples: B2 growth 48%, B2 now 40% of revenue, developers data up 80%, B2 Reserve initial ramp, channel partners, etc. But does management explicitly say that what is happening now is disproportionately large compared to the company's small size? They mention growth rates, but that's typical. They talk about $100 billion market opportunity, but that's TAM. They mention B2 Reserve revenue increasing each month, but not that it's huge relative to company. They mention nine of top-20 accounts are developers, but not that it's outsized. They mention channel partners as sales force multiplier, but not that it's already arriving at scale. They mention "we are still early in our life as a Public Company with funds to pursue our $100 billion market opportunity." That's generic. They don't explicitly say "this single contract is as big as our current revenue" or "we are handling volumes that would have been out of reach." They do say "B2 Reserve show a nice initial ramp in demand with revenue increasing each month" but that's not disproportionate. They mention "we are not for example seeing as much benefit to-date, as we expected from our growth initiatives" which suggests they are not seeing outsized results. So no clear statement of disproportion. The question asks if management conveys that the business is visibly outgrowing the company's own current size. They report strong growth but not that it's disproportionately large relative to smallness. They don't say "we are small and this is huge." They mention growth rates but that's normal. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.